<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Exp Ther Med</journal-id><journal-id journal-id-type="iso-abbrev">Exp Ther Med</journal-id><journal-id journal-id-type="publisher-id">ETM</journal-id><journal-title-group><journal-title>Experimental and Therapeutic Medicine</journal-title></journal-title-group><issn pub-type="ppub">1792-0981</issn><issn pub-type="epub">1792-1015</issn><publisher><publisher-name>D.A. Spandidos</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23596496</article-id><article-id pub-id-type="pmc">3627469</article-id><article-id pub-id-type="doi">10.3892/etm.2013.965</article-id><article-id pub-id-type="publisher-id">etm-05-04-1244</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>A clinical study of transcranial ultrasound as an adjuvant therapy for progressive cerebral infarction</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>GAO</surname><given-names>XIUJU</given-names></name><xref ref-type="corresp" rid="c1-etm-05-04-1244"/></contrib><aff id="af1-etm-05-04-1244">Department of Neurology, The First Affiliated Hospital, Henan University of Science and Technology, Luoyang 471003, 
<country>P.R. China</country></aff></contrib-group><author-notes><corresp id="c1-etm-05-04-1244">Correspondence to: Professor Xiuju Gao, Department of Neurology, The First Affiliated Hospital, Henan University of Science and Technology, No.24 Jinghua Road, Luoyang 471003, P.R. China, E-mail: <email>xjgaocn@163.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>4</month><year>2013</year></pub-date><pub-date pub-type="epub"><day>19</day><month>2</month><year>2013</year></pub-date><pub-date pub-type="pmc-release"><day>19</day><month>2</month><year>2013</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the
							<pub-date pub-type="epub"/>. --><volume>5</volume><issue>4</issue><fpage>1244</fpage><lpage>1246</lpage><history><date date-type="received"><day>06</day><month>12</month><year>2012</year></date><date date-type="accepted"><day>24</day><month>1</month><year>2013</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2013, Spandidos Publications</copyright-statement><copyright-year>2013</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0"><license-p>This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.</license-p></license></permissions><abstract><p>The present study aimed to investigate the clinical efficacy of transcranial ultrasound as an adjuvant therapy in combination with small doses of urokinase (UK) for the treatment of progressive cerebral infarction. Sixty-one eligible patients with progressive cerebral infarction were successively and randomly assigned into one of the following groups; 30 patients to the treatment group (transcranial ultrasound + small doses of UK) and 31 patients to the control group (single small doses of UK). Based on conventional therapy, patients in the treatment group received transcranial ultrasound. The neural function deficit scale and curative effect scores of the two groups were recorded before treatment and on the 7th and 14th days after treatment. No differences in the neural function deficit scale between the two groups was observed before treatment, however, on the 7th and 14th days after treatment, a significant decrease was evident in the treatment group (P&#x0003c;0.01). The overall response rate was 100% in the treatment group and 74.2% in the control group, with a significant difference (P&#x0003c;0.01). Transcranial ultrasound is able to contribute to the thrombolytic effects of UK and prevent the progression of thrombi, subsequently aiding the recovery of neural functions.</p></abstract><kwd-group><kwd>transcranial ultrasound thrombolysis</kwd><kwd>progressive cerebral infarction</kwd><kwd>urokinase</kwd></kwd-group></article-meta></front><body><sec><title>Introduction</title><p>Progressive ischemic stroke refers to the symptoms of neurological deficit present after ischemic stroke which demonstrate progressive aggravation and continue until further severe neurological deficits appear within 48 h (<xref rid="b1-etm-05-04-1244" ref-type="bibr">1</xref>). Progressive ischemic stroke accounts for 30% of all incidences of stroke and is associated with an increased rate of morbidity and mortality. Due to the difficulty in treating such cerebrovascular diseases (<xref rid="b2-etm-05-04-1244" ref-type="bibr">2</xref>), much attention has been devoted to this group of diseases by clinicians. In this study, we report 30 cases of clinical observation and analysis of transcranial ultrasound combined with small doses of urokinase (UK) for the treatment of progressive cerebral infarction.</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><sec><title>Clinical data</title><p>Sixty-one patients from The First Affiliated Hospital, Henan University of Science and Technology (Luoyang, China) were enrolled between October 2005 and October 2010. Each patient&#x02019;s diagnostic criteria met with the international diagnostic criteria of cerebral stroke (<xref rid="b3-etm-05-04-1244" ref-type="bibr">3</xref>). Patients were successively and randomly assigned into one of the following groups; 30 patients to the treatment group (small doses of UK + transcranial ultrasound) and 31 patients to the control group (single small doses of UK). No significant differences in age, onset time, complications and degree of nervous functional defects were observed between the two groups (P&#x0003e;0.05). Eligibility criteria for patients included: i) aged 40&#x02013;75 years old; ii) clinical features were in accordance with internal carotid artery system cerebral infarction; iii) onset time was &#x0003c;72 h and the primary stroke symptoms of the nervous system and signs displayed continued progressive aggravation under doctor supervision and medical intervention; iv) cerebral hemorrhage was ruled out by cerebral CT/MRI; v) patients and/or their families provided written informed consent. This study was conducted in accordance with the declaration of Helsinki. This study was conducted with approval from the Ethics Committee of The First Affiliated Hospital, Henan University of Science and Technology.</p></sec><sec><title>Treatment</title><p>In the treatment group, 100 ml UK (250,000 units) + physiological saline was intravenously administered within 30 min. Simultaneously, transcranial ultrasound therapy combined with ultrasound through the transtemporal window of the lesion side was performed once a day for 20 min, for a total of 5 days. In the control group, 100 ml UK (250,000 units) + physiological saline was administered, and at the same time a therapeutic instrument was worn without any sound device, with the same treatment regimen as the treatment group. Both groups of patients were routinely administered drugs to promote blood circulation and remove blood stasis (such as Xuesaitong or Shuxuetong) and edaravone, a cerebral protective agent. Patients complicated with diabetes, hypertension or hyperlipidemia were administered the relevant treatment.</p></sec><sec><title>Observation</title><p>The two groups of patients routinely underwent cerebral CT/MRI, as well as examination of hemagglutination, blood routine, blood glucose, hepatonephric function and electrolyte levels before and after treatment. Patients were evaluated using the neural function deficit scale before treatment, and on the 7th and 14th days after treatment by neurologists.</p></sec><sec><title>Evaluation of efficacy</title><p>According to the latest diagnostic criteria for cerebral stroke modified in 2012, the degrees of clinical neurological deficit and the qualities of lives within each group of patients were scored and their efficacies determined (<xref rid="b4-etm-05-04-1244" ref-type="bibr">4</xref>): i) almost cured: the deficit score was decreased by 91&#x02013;100%, with a grade 0 disability; ii) significantly improved: the deficit score was decreased by 46&#x02013;90%, with a grade 1&#x02013;3 disability; iii) improved: the deficit score was decreased by 18&#x02013;45%, with independent life; iv) invalid: the deficit score was decreased by &#x0003c;17%; v) worse: the deficit score was increased by &#x0003e;18% or mortality.</p></sec><sec><title>Statistical analysis</title><p>The SPSS 10.0 software was used to analyze the data. The measurement data were measured by &#x003c7;<sup>2</sup> inspection and are presented as mean &#x000b1; SD.</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Neural function deficit scale</title><p>There was no significant difference in the neural function deficit scale between the two groups before treatment, however, a significant difference was evident after treatment. The Scandinavian Stroke Scale (SSS) rating decreased significantly on the 7th and 14th days after administration of treatment within the treatment group, with a significant difference before treatment compared with the control group (P&#x0003c;0.01, <xref rid="t1-etm-05-04-1244" ref-type="table">Table I</xref>).</p></sec><sec><title>Comparison of clinical efficacy</title><p>The overall response rate was 100% in the treatment group and 74.2% in the control group, with a significant difference (P&#x0003c;0.01, <xref rid="t2-etm-05-04-1244" ref-type="table">Table II</xref>).</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>Progressive cerebral stroke is referred to as the increase of neurological deficit within several hours of the onset of disease, generally caused by the amplification of arterial thrombosis, with the exception of hematoma and edema (<xref rid="b5-etm-05-04-1244" ref-type="bibr">5</xref>). Around one-third of patients with stroke develop progressive stroke (<xref rid="b6-etm-05-04-1244" ref-type="bibr">6</xref>), which carries a significantly enhanced mortality and disability rate (<xref rid="b7-etm-05-04-1244" ref-type="bibr">7</xref>), causing an increasing number of difficulties in diagnosis and treatment and doctor-patient disputes. Hemodynamic pathogenesis is characterized by decreased perfusion in the ischemic zone causing collateral circulation insufficiency and progressive circulatory failure, followed by irreversible damage and penumbra expansion in the ischemic penumbra, which leads to the viability of brain cells in this area shortening and becoming unable to transfer information to other cells (<xref rid="b8-etm-05-04-1244" ref-type="bibr">8</xref>). The number and length of time that these type of cells exist is unstable. These cells are able to evolve into necrotic tissue or normal brain tissue. Therefore, this process may only be prevented after timely rescue of this penumbra (<xref rid="b9-etm-05-04-1244" ref-type="bibr">9</xref>). In previous years, ultra-early intravenous thrombolysis has achieved significant efficacies for the treatment of acute cerebral infarction (<xref rid="b10-etm-05-04-1244" ref-type="bibr">10</xref>), however, its time was limited to within 3&#x02013;6 h. There were different time limits, treatment effects and safety views with respect to the application of UK thrombolysis in treatment of progressive cerebral stroke (<xref rid="b11-etm-05-04-1244" ref-type="bibr">11</xref>,<xref rid="b12-etm-05-04-1244" ref-type="bibr">12</xref>). A safe and effective method to extend the time window would prevent further progression in cerebral infarction patients occurring. Reducing the disability rate and improving patients&#x02019; quality of life is of great importance to clinicans.</p><p>In the present study, transcranial ultrasound therapy was used with an ultrasound instrument with a specific power and frequency (<xref rid="b13-etm-05-04-1244" ref-type="bibr">13</xref>). In 1976, Professor Lang Hongzhi of our department published the first international article on ultrasonic treatment of cerebrovascular disease (<xref rid="b14-etm-05-04-1244" ref-type="bibr">14</xref>). Trubestein <italic>et al</italic> reported that ultrasound was capable of destroying and removing intravascular thrombi (<xref rid="b15-etm-05-04-1244" ref-type="bibr">15</xref>). Subsequent <italic>in vitro</italic> and <italic>in vivo</italic> studies on ultrasound thrombolysis then confirmed that low-frequency ultrasound is able to penetrate the skull and enhance the thrombolytic effect of rtPA, with a good safety profile, which did not damage the blood-brain barrier (<xref rid="b16-etm-05-04-1244" ref-type="bibr">16</xref>,<xref rid="b17-etm-05-04-1244" ref-type="bibr">17</xref>). In recent years, a large number of studies have reported that the application of diagnostic transcranial Doppler ultrasonography may enhance the thrombolytic effects of rtPA for the treatment of ischemic cerebral infarction (<xref rid="b18-etm-05-04-1244" ref-type="bibr">18</xref>). Our department had previously applied UK combined with transcranial ultrasound for the treatment of early acute cerebral infarction and achieved satisfactory results. Transcranial ultrasound with a specific power and frequency is capable of directly acting on the cerebral lesion site through the skull to promote migration of the thrombolytic drug to the blood clot by cleavage of cross-linked fibrin (<xref rid="b19-etm-05-04-1244" ref-type="bibr">19</xref>), subsequently aiding the thrombolytic effect. The instrument we used previously to perform ultrasound treatment was the type LHZ produced by the Kang Liya (Hong Kong Group) Biological Technology Co., Ltd. (Luoyang, China). It consisted of an ultrasonic generator, a treatment sound head and a fixed head frame. A 0.75-W/cm<sup>2</sup> pulsed ultrasound was generated with a 3-cm<sup>2</sup> sound head area and a 800-kHz ultrasonic frequency. The treatment was performed by fixing the sound head on the temporal window of the lesion side and coating the couplant on the surface of the sound head to ensure that the ultrasound penetrated through the skull. During intravenous infusion of UK, the ultrasonic treatment was administered for the same 20 min. <italic>In vitro</italic> tests, animal models and clinical studies have since confirmed that the ultrasound aids a unique biological effect of directly dissolving thrombi and enhancing the effects of thrombolytic drugs (<xref rid="b20-etm-05-04-1244" ref-type="bibr">20</xref>&#x02013;<xref rid="b22-etm-05-04-1244" ref-type="bibr">22</xref>). Its mechanism of action may be summarized as cavitation, micro-flow effect, vibration causing mechanical action, thermal effects, sonochemistry action, ultrasonic penetration action, enhanced fibrinolytic activity, enhanced fiber drugs effect, shortened blood reperfusion time and reversal poisoning (<xref rid="b23-etm-05-04-1244" ref-type="bibr">23</xref>).</p><p>The results of this study demonstrated that the neural function deficit scale of the transcranial ultrasound + small doses of UK group decreased significantly on the 7th and 14th days after treatment compared with the control group (P&#x0003c;0.01). This revealed that transcranial ultrasound contributes to the thrombolysis of UK and may thus be important for the treatment of progressive cerebral infarction by preventing thrombi from progressing and promoting the recovery of neural functions (<xref rid="b23-etm-05-04-1244" ref-type="bibr">23</xref>). In addition, transcranial ultrasound caused no pain, leading to a high patient compliance, with a quick curative effect and no cell damage caused. Owing to its mechanical effects, ultrasound is able to improve the metabolism levels of brain cells, subsequently aiding the recovery of brain cell function and preventing cell death. Followed by the improvement of brain function (<xref rid="b25-etm-05-04-1244" ref-type="bibr">25</xref>), the recovery of patient&#x02019;s paralyzed limb, speech recovery, improved memory, which was worthy of clinical application.</p></sec></body><back><ref-list><title>References</title><ref id="b1-etm-05-04-1244"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dreier</surname><given-names>JP</given-names></name></person-group><article-title>The role of spreading depression, spreading depolarization and spreading ischemia in neurological disease</article-title><source>Nat Med</source><volume>17</volume><fpage>439</fpage><lpage>447</lpage><year>2011</year><pub-id pub-id-type="pmid">21475241</pub-id></element-citation></ref><ref id="b2-etm-05-04-1244"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miedema</surname><given-names>I</given-names></name><name><surname>Luijckx</surname><given-names>GJ</given-names></name><name><surname>Uyttenboogaart</surname><given-names>M</given-names></name></person-group><article-title>Bleeding risk with ischemic stroke therapy</article-title><source>JAMA</source><volume>308</volume><fpage>1318</fpage><lpage>1319</lpage><year>2012</year><pub-id pub-id-type="pmid">23032535</pub-id></element-citation></ref><ref id="b3-etm-05-04-1244"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jamieson</surname><given-names>DG</given-names></name></person-group><article-title>Diagnosis of ischemic stroke</article-title><source>Am J Med</source><volume>122</volume><issue>4 Suppl 2</issue><fpage>S14</fpage><lpage>S20</lpage><year>2009</year><pub-id pub-id-type="pmid">19332239</pub-id></element-citation></ref><ref id="b4-etm-05-04-1244"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sobolewski</surname><given-names>P</given-names></name><name><surname>Sledzi&#x00144;ska</surname><given-names>M</given-names></name><name><surname>Szczuchniak</surname><given-names>W</given-names></name><name><surname>Grzesik</surname><given-names>M</given-names></name><name><surname>Sobota</surname><given-names>A</given-names></name><name><surname>Hatalska-Zerebiec</surname><given-names>R</given-names></name></person-group><article-title>Intravenous thrombolysis patients with acute ischemic stroke - the analysis of the 100 cases. Part II. Neuroimaging, the analysis of hemorrhagic complications and deaths</article-title><source>Przegl Lek</source><volume>69</volume><fpage>242</fpage><lpage>246</lpage><year>2012</year><comment>(In Polish).</comment><pub-id pub-id-type="pmid">23094436</pub-id></element-citation></ref><ref id="b5-etm-05-04-1244"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kenet</surname><given-names>G</given-names></name><name><surname>L&#x000fc;tkhoff</surname><given-names>LK</given-names></name><name><surname>Albisetti</surname><given-names>M</given-names></name><etal/></person-group><article-title>Impact of thrombophilia on risk of arterial ischemic stroke or cerebral sinovenous thrombosis in neonates and children: a systematic review and meta-analysis of observational studies</article-title><source>Circulation</source><volume>121</volume><fpage>1838</fpage><lpage>1847</lpage><year>2010</year><pub-id pub-id-type="pmid">20385928</pub-id></element-citation></ref><ref id="b6-etm-05-04-1244"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stanley</surname><given-names>NC</given-names></name></person-group><article-title>Preventing recurrent ischemic stroke: a 3-step plan</article-title><source>J Fam Pract</source><volume>54</volume><fpage>412</fpage><lpage>422</lpage><year>2005</year><pub-id pub-id-type="pmid">15865898</pub-id></element-citation></ref><ref id="b7-etm-05-04-1244"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pikija</surname><given-names>S</given-names></name><name><surname>Cvetko</surname><given-names>D</given-names></name><name><surname>Maloj&#x0010d;i&#x00107;</surname><given-names>B</given-names></name><etal/></person-group><article-title>A population-based prospective 24-month study of stroke: incidence and 30-day case-fatality rates of first-ever strokes in Croatia</article-title><source>Neuroepidemiology</source><volume>38</volume><fpage>164</fpage><lpage>171</lpage><year>2012</year><pub-id pub-id-type="pmid">22473420</pub-id></element-citation></ref><ref id="b8-etm-05-04-1244"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>M</given-names></name><name><surname>Ginsberg</surname><given-names>M</given-names></name></person-group><article-title>Current concepts of the ischemic penumbra</article-title><source>Stroke</source><volume>35</volume><fpage>2657</fpage><lpage>2658</lpage><year>2004</year></element-citation></ref><ref id="b9-etm-05-04-1244"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonz&#x000e1;lez</surname><given-names>RG</given-names></name></person-group><article-title>Imaging-guided acute ischemic stroke therapy: from &#x02018;time is brain&#x02019; to &#x02018;physiology is brain&#x02019;</article-title><source>AJNR Am J Neuroradiol</source><volume>27</volume><fpage>728</fpage><lpage>735</lpage><year>2006</year><pub-id pub-id-type="pmid">16611754</pub-id></element-citation></ref><ref id="b10-etm-05-04-1244"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tirschwell</surname><given-names>DL</given-names></name><name><surname>Coplin</surname><given-names>WM</given-names></name><name><surname>Becker</surname><given-names>KJ</given-names></name><etal/></person-group><article-title>Intra-arterial urokinase for acute ischemic stroke: factors associated with complications</article-title><source>Neurology</source><volume>57</volume><fpage>1100</fpage><lpage>1103</lpage><year>2001</year><pub-id pub-id-type="pmid">11571343</pub-id></element-citation></ref><ref id="b11-etm-05-04-1244"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>RS</given-names></name><name><surname>Ok</surname><given-names>YC</given-names></name><name><surname>Lim</surname><given-names>JS</given-names></name><name><surname>Lim</surname><given-names>BC</given-names></name><name><surname>Cho</surname><given-names>KY</given-names></name><name><surname>Lee</surname><given-names>MC</given-names></name></person-group><article-title>Outcome evaluation of intravenous infusion of urokinase for acute ischemic stroke</article-title><source>Chonnam Med J</source><volume>48</volume><fpage>52</fpage><lpage>56</lpage><year>2012</year><pub-id pub-id-type="pmid">22570816</pub-id></element-citation></ref><ref id="b12-etm-05-04-1244"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Macleod</surname><given-names>MR</given-names></name><name><surname>Davis</surname><given-names>SM</given-names></name><name><surname>Mitchell</surname><given-names>PJ</given-names></name><etal/></person-group><article-title>Results of a multi-centre, randomised controlled trial of intra-arterial urokinase in the treatment of acute posterior circulation ischaemic stroke</article-title><source>Cerebrovasc Dis</source><volume>20</volume><fpage>12</fpage><lpage>17</lpage><year>2005</year><pub-id pub-id-type="pmid">15925877</pub-id></element-citation></ref><ref id="b13-etm-05-04-1244"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levi</surname><given-names>CR</given-names></name><name><surname>Selmes</surname><given-names>C</given-names></name><name><surname>Chambers</surname><given-names>BR</given-names></name></person-group><article-title>Transcranial ultrasound-clinical applications in cerebral ischaemia</article-title><source>Australian Prescriber</source><volume>24</volume><fpage>137</fpage><lpage>140</lpage><year>2001</year></element-citation></ref><ref id="b14-etm-05-04-1244"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Cerebrovascular Disease Treatment Group of the Third People&#x02019;s Hospital of Luoyang City, Henan Province</collab></person-group><article-title>Clinical analysis of 1005 cases of hemiplegia caused by ultrasound treatment of cerebrovascular disease</article-title><source>Chinese Journal of Internal Medicine</source><volume>16</volume><fpage>220</fpage><year>1976</year></element-citation></ref><ref id="b15-etm-05-04-1244"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trubestein</surname><given-names>R</given-names></name><name><surname>Engel</surname><given-names>HR</given-names></name><name><surname>Ezel</surname><given-names>F</given-names></name><etal/></person-group><article-title>Thrombolysis by ultrasound</article-title><source>Clin Sci Mol Med</source><volume>51</volume><fpage>697</fpage><lpage>698</lpage><year>1976</year></element-citation></ref><ref id="b16-etm-05-04-1244"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitragotri</surname><given-names>S</given-names></name><name><surname>Blankschtein</surname><given-names>D</given-names></name><name><surname>Langer</surname><given-names>R</given-names></name></person-group><article-title>Transdermal drug delivery using low-frequency sonophoresis</article-title><source>Pharm Res</source><volume>13</volume><fpage>411</fpage><lpage>420</lpage><year>1996</year><pub-id pub-id-type="pmid">8692734</pub-id></element-citation></ref><ref id="b17-etm-05-04-1244"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daffertshofer</surname><given-names>M</given-names></name><name><surname>Gass</surname><given-names>A</given-names></name><name><surname>Ringleb</surname><given-names>P</given-names></name><etal/></person-group><article-title>Transcranial low-frequency ultrasound-mediated thrombolysis in brain ischemia</article-title><source>Stroke</source><volume>36</volume><fpage>1441</fpage><lpage>1446</lpage><year>2005</year><pub-id pub-id-type="pmid">15947262</pub-id></element-citation></ref><ref id="b18-etm-05-04-1244"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cherniavsky</surname><given-names>EA</given-names></name><name><surname>Strakha</surname><given-names>IS</given-names></name><name><surname>Adzerikho</surname><given-names>IE</given-names></name><name><surname>Shkumatov</surname><given-names>VM</given-names></name></person-group><article-title>Effects of low frequency ultrasound on some properties of fibrinogen and its plasminolysis</article-title><source>BMC Biochem</source><volume>12</volume><fpage>60</fpage><year>2011</year><pub-id pub-id-type="pmid">22112213</pub-id></element-citation></ref><ref id="b19-etm-05-04-1244"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meunier</surname><given-names>JM</given-names></name><name><surname>Holland</surname><given-names>CK</given-names></name><name><surname>Pancioli</surname><given-names>AM</given-names></name><name><surname>Lindsell</surname><given-names>CJ</given-names></name><name><surname>Shaw</surname><given-names>GJ</given-names></name></person-group><article-title>Effect of low frequency ultrasound on combined rt-PA and eptifibatide thrombolysis in human clots</article-title><source>Thromb Res</source><volume>123</volume><fpage>528</fpage><lpage>536</lpage><year>2009</year><pub-id pub-id-type="pmid">18619651</pub-id></element-citation></ref><ref id="b20-etm-05-04-1244"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>J</given-names></name><name><surname>Fang</surname><given-names>C</given-names></name><name><surname>Sung</surname><given-names>KC</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name></person-group><article-title>Effect of low frequency ultrasound on the in vitro percutaneous absorption of clobetasol 17-propionate</article-title><source>Int J Pharm</source><volume>191</volume><fpage>33</fpage><lpage>42</lpage><year>1999</year><pub-id pub-id-type="pmid">10556738</pub-id></element-citation></ref><ref id="b21-etm-05-04-1244"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emerson</surname><given-names>PF</given-names></name><name><surname>Ruan</surname><given-names>J</given-names></name><name><surname>McLaughlin</surname><given-names>BE</given-names></name><name><surname>Keshaviah</surname><given-names>PR</given-names></name><name><surname>DeLeo</surname><given-names>MA</given-names></name><name><surname>Piscopo</surname><given-names>D</given-names></name></person-group><article-title>Effect of low-frequency ultrasound on peritoneal transport in rabbits</article-title><source>Adv Perit Dial</source><volume>13</volume><fpage>77</fpage><lpage>80</lpage><year>1997</year><pub-id pub-id-type="pmid">9360655</pub-id></element-citation></ref><ref id="b22-etm-05-04-1244"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hitchcock</surname><given-names>KE</given-names></name><name><surname>Holland</surname><given-names>CK</given-names></name></person-group><article-title>Ultrasound-assisted thrombolysis for stroke therapy: better thrombus break-up with bubbles</article-title><source>Stroke</source><volume>41</volume><fpage>S50</fpage><lpage>S53</lpage><year>2010</year><pub-id pub-id-type="pmid">20876505</pub-id></element-citation></ref><ref id="b23-etm-05-04-1244"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Francis</surname><given-names>CW</given-names></name><name><surname>Suchkova</surname><given-names>VN</given-names></name></person-group><article-title>Ultrasound and thrombolysis</article-title><source>Vasc Med</source><volume>6</volume><fpage>181</fpage><lpage>187</lpage><year>2001</year><pub-id pub-id-type="pmid">11789973</pub-id></element-citation></ref><ref id="b24-etm-05-04-1244"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meunier</surname><given-names>JM</given-names></name><name><surname>Holland</surname><given-names>CK</given-names></name><name><surname>Porter</surname><given-names>TM</given-names></name><name><surname>Lindsell</surname><given-names>CJ</given-names></name><name><surname>Shaw</surname><given-names>GJ</given-names></name></person-group><article-title>Combination treatment with rt-PA is more effective than rt-PA alone in an in vitro human clot model</article-title><source>Curr Neurovasc Res</source><volume>8</volume><fpage>305</fpage><lpage>312</lpage><year>2011</year><pub-id pub-id-type="pmid">22023612</pub-id></element-citation></ref><ref id="b25-etm-05-04-1244"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Xue</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Shang</surname><given-names>X</given-names></name></person-group><article-title>Additive effect of low-frequency ultrasound and endothelial monocyte-activating polypeptide II on blood-tumor barrier in rats with brain glioma</article-title><source>Neurosci Lett</source><volume>481</volume><fpage>21</fpage><lpage>25</lpage><year>2010</year><pub-id pub-id-type="pmid">20600613</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap id="t1-etm-05-04-1244" orientation="portrait" position="float"><label>Table I</label><caption><p>Neural function deficit scale before and after treatment in the two groups (mean &#x000b1; SD).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1">Group</th><th align="center" valign="middle" rowspan="1" colspan="1">n</th><th align="center" valign="middle" rowspan="1" colspan="1">Before treatment</th><th align="center" valign="middle" rowspan="1" colspan="1">7 days after treatment</th><th align="center" valign="middle" rowspan="1" colspan="1">14 days after treatment</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Treatment</td><td align="center" valign="top" rowspan="1" colspan="1">30</td><td align="left" valign="top" rowspan="1" colspan="1">21.01&#x000b1;7.8</td><td align="right" valign="top" rowspan="1" colspan="1">15.9&#x000b1;6.21</td><td align="center" valign="top" rowspan="1" colspan="1">9.91&#x000b1;8.91<xref rid="tfn2-etm-05-04-1244" ref-type="table-fn"><sup>a</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Control</td><td align="center" valign="top" rowspan="1" colspan="1">31</td><td align="left" valign="top" rowspan="1" colspan="1">20.82&#x000b1;9.53</td><td align="right" valign="top" rowspan="1" colspan="1">20.12&#x000b1;9.53</td><td align="center" valign="top" rowspan="1" colspan="1">18.3&#x000b1;9.58<xref rid="tfn3-etm-05-04-1244" ref-type="table-fn"><sup>b</sup></xref></td></tr></tbody></table><table-wrap-foot><fn id="tfn1-etm-05-04-1244"><p>Compared with the control group,</p></fn><fn id="tfn2-etm-05-04-1244"><label>a</label><p>P&#x0003c;0.01; compared with the treatment group,</p></fn><fn id="tfn3-etm-05-04-1244"><label>b</label><p>P&#x0003c;0.01.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2-etm-05-04-1244" orientation="portrait" position="float"><label>Table II</label><caption><p>Comparison of efficacy between the two groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="2" colspan="1">Group</th><th align="center" valign="bottom" rowspan="2" colspan="1">n</th><th colspan="6" align="center" valign="bottom" rowspan="1">Cases (%)
<hr/></th></tr><tr><th align="center" valign="bottom" rowspan="1" colspan="1">Almost cured</th><th align="center" valign="bottom" rowspan="1" colspan="1">Significantly improved</th><th align="center" valign="bottom" rowspan="1" colspan="1">Improved</th><th align="center" valign="bottom" rowspan="1" colspan="1">No change</th><th align="center" valign="bottom" rowspan="1" colspan="1">Significant efficacy</th><th align="center" valign="bottom" rowspan="1" colspan="1">Overall response rate</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Treatment</td><td align="center" valign="top" rowspan="1" colspan="1">30</td><td align="center" valign="top" rowspan="1" colspan="1">12 (40)</td><td align="center" valign="top" rowspan="1" colspan="1">16 (53.3)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (6.7)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="top" rowspan="1" colspan="1">28 (93.3)<xref rid="tfn5-etm-05-04-1244" ref-type="table-fn"><sup>a</sup></xref></td><td align="center" valign="top" rowspan="1" colspan="1">30 (100)<xref rid="tfn6-etm-05-04-1244" ref-type="table-fn"><sup>b</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Control</td><td align="center" valign="top" rowspan="1" colspan="1">31</td><td align="center" valign="top" rowspan="1" colspan="1">5 (16.1)</td><td align="center" valign="top" rowspan="1" colspan="1">10 (32.3)</td><td align="left" valign="top" rowspan="1" colspan="1">8 (25.8)</td><td align="left" valign="top" rowspan="1" colspan="1">8 (25.8)</td><td align="center" valign="top" rowspan="1" colspan="1">15 (48.4)</td><td align="center" valign="top" rowspan="1" colspan="1">23 (74.2)</td></tr></tbody></table><table-wrap-foot><fn id="tfn4-etm-05-04-1244"><p>Compared with the control group, the significant efficacy</p></fn><fn id="tfn5-etm-05-04-1244"><label>a</label><p>P&#x0003c;0.05; the overall response rate</p></fn><fn id="tfn6-etm-05-04-1244"><label>b</label><p>P&#x0003c;0.01.</p></fn></table-wrap-foot></table-wrap></floats-group></article>